<DOC>
	<DOCNO>NCT01277042</DOCNO>
	<brief_summary>This study design evaluate immunogenicity safety GSK Biologicals ' human papillomavirus ( HPV ) vaccine adult female subject age 26-45 year . One group subject receive HPV vaccine group receive active control ( GSK Biologicals ' hepatitis B vaccine ) . Immunogenicity data HPV group compare HPV group include NCT00779766 study ( age 18-25 year ) .</brief_summary>
	<brief_title>Study Assess Immune Responses Safety GSK-580299 Vaccine Healthy Women ( 26 45 Years )</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 1 , December 2010 , lead : - The removal 3 outcome measure - The update 1 outcome measure</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent prior study enrolment . Healthy adult female Chinese origin reside China include 26 45 year age time first vaccination . Subjects investigator believe comply requirement protocol enrol study . Healthy subject establish medical history historydirected clinical examination enter study . Subjects must pregnant . Absence pregnancy verify urine pregnancy test vaccination . Subjects must nonchildbearing potential , i.e. , current tubal ligation , hysterectomy , ovariectomy , one year postmenopausal , childbearing potential , must abstinent practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination agree continue precaution entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . A subject planning become pregnant , likely become pregnant planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeeding subject must least three month postpregnancy breastfeed enter study . Previous vaccination HPV plan administration HPV vaccine foreseen protocol study period . Previous administration 3Odesacyl4'monophosphoryl lipid A AS04 adjuvant . Previous vaccination hepatitis B plan administration hepatitis B vaccine foreseen study protocol study period . History hepatitis B infection . Known exposure hepatitis B within previous 6 week . History chronic condition ( ) require treatment cancer autoimmune disease . History allergic disease , suspect allergy reaction likely exacerbate component vaccine ( e.g . aluminium ) . Hypersensitivity latex . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Immune response</keyword>
	<keyword>Human papillomavirus</keyword>
	<keyword>China</keyword>
</DOC>